Effects of Teriparatide Compared with Risedronate on the Risk of Fractures in Subgroups of Postmenopausal Women with Severe Osteoporosis: The VERO Trial

Piet Geusens, Fernando Marin, David L. Kendler, Luis A. Russo, Cristiano A. F. Zerbini, Salvatore Minisola, Jean Jacques Body, Eric Lespessailles, Susan L. Greenspan, Alicia Bagur, Jan J. Stepan, Peter Lakatos, Enrique Casado, Ruediger Moericke, Pedro Lopez-Romero, Astrid Fahrleitner-Pammer

Research output: Contribution to journalArticleAcademicpeer-review

Original languageEnglish
Pages (from-to)783-794
Number of pages12
JournalJournal of Bone and Mineral Research
Volume33
Issue number5
DOIs
Publication statusPublished - 1 May 2018

Keywords

  • TERIPARATIDE
  • VERTEBRAL FRACTURES
  • POSTMENOPAUSAL OSTEOPOROSIS
  • BISPHOSPHONATES
  • SUBGROUP ANALYSIS
  • BONE-MINERAL DENSITY
  • RANDOMIZED CONTROLLED-TRIAL
  • YEARLY ZOLEDRONIC ACID
  • NONVERTEBRAL FRACTURES
  • HIP FRACTURE
  • ALENDRONATE
  • BMD
  • ABALOPARATIDE
  • PREVENTS

Cite this